Asimov launched its AAV Edge Stable Producer system with the goal of addressing the shortcomings of traditional transient transfection-based production and bringing AAV manufacturing standards closer to those established for antibody-based biologics, according to Alec Nielsen, PhD, co-founder and CEO of the company.
A major challenge in AAV gene therapy has been developing scalable, cost-efficient processes to reliably produce high-quality vectors. Most programs still depend on transient production, which requires multiple GMP plasmids to be transfected every batch. This approach drives up costs, introduces supply chain risk, limits bioreactor scalability, and can potentially result in inconsistent product quality, he continues.
By stably integrating all essential viral genes into the genome of HEK293 cells, Asimov generates high-titer, clonal producer cell lines, explains Nielsen. Stable clones eliminate the need for costly GMP plasmids, enable straightforward scaleup in bioreactors, and minimize batch-to-batch variability, he points out, adding that the result is lower manufacturing cost, more consistent product quality, and the potential for safer, more effective AAV gene therapies.
An Asimov spokesperson says the new offering delivers research cell banks (RCBs) within 20 weeks that contain the desired capsid and transgene. Therapeutic developers receive clonal, suspension-adapted, fully stable AAV HEK293 producer cell lines that enable reliable manufacture of gene therapies at scale, with titers up to 6E15 vg/L before purification, states the spokesperson.
“It’s no secret that the gene therapy field has gone through several painful years recently, but the fact is that gene therapy remains our best shot at treating many of the world’s most intractable diseases. We believe in the potential of this modality, and stand alongside the patients and scientific pioneers who continue to push the field forward,” says Nielsen.
“Together, we’re pulling every lever available to improve scalability, safety, efficacy, quality, and cost. Stable producer cell lines are one of the technologies needed to unlock the next generation of gene therapies. I’m incredibly proud of our team for achieving this technical milestone in synthetic biology, and excited by the validation we’re receiving from pharma partners on their gene therapy programs.”